Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $5 | $0 | $0 |
| SG&A Expenses | $3 | $5 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | $0 | $0 |
| Operating Expenses | $3 | $3 | $0 | $0 |
| Operating Income | -$4 | -$3 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$7 | -$4 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$6 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS | -1.94 | -1 | -0.92 | -0.78 |
| % Growth | -94% | -8.7% | -17.9% | – |
| EPS Diluted | -1.94 | -1 | -0.92 | -0.78 |
| Weighted Avg Shares Out | 4 | 4 | 0 | 0 |
| Weighted Avg Shares Out Dil | 4 | 4 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$2 | -$3 | -$0 |
| % Margin | – | – | – | – |